Bristol-Myers Squibb plans to bring immunomodulator CTLA4Ig into Phase II this year for psoriasis.
Executive Summary
BRISTOL-MYERS SQUIBB TAKING IMMUNOMODULAR CTLA4Ig INTO PHASE II BY YEAR END to evaluate the drug's efficacy in psoriasis. CTLA4Ig is an immunomodulator that "essentially works by blocking the activation of immune system T cells, which prevents the body from recognizing transplanted tissue as foreign or mistakenly rejecting its own tissue," Bristol-Myers Squibb explains.